Evoke Pharma Inc (EVOK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Evoke Pharma Inc (EVOK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH137453D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Evoke Pharma Inc (Evoke Pharma) is a specialty pharmaceutical company that develops drugs to treat gastrointestinal diseases. The company's lead product candidate EVK-001 is under clinical development that provides relief from the symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Its Gimoti, is in late stage clinical testing for the treatment of diabetic gastroparesis. Evoke Pharma provides therapies for various gastrointestinal disorders such as constipation, motility disorder, GERD, peptic ulcers and irritable bowel syndrome and gastroparesis. The company operates through other commercial organizations and external consultants to develop novel product candidates. It also develops programs with associated clinical data, products containing previously approved compounds, and others. Evoke Pharma is headquartered in Solana Beach, California, the US.

Evoke Pharma Inc (EVOK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Evoke Pharma Inc, Medical Devices Deals, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deal Details

Partnerships

Evoke Pharma Enters into Agreement with Thermo Fisher Scientific

Evoke Pharma Enters into Partnership with Spaulding Clinical Research

Equity Offering

Evoke Pharma Plans to Raise up to USD16 Million in Public Offering of Shares

Evoke Pharma Raises USD8 Million in Public Offering of Shares

Evoke Pharma Raises USD4.5 Million in Registered Direct Offering

Evoke Pharma to Raise USD10 Million in Registered Direct Offering

Evoke Pharma Raises USD5 Million in Public Offering of Shares

Evoke Pharma to Raise Funds through Public Offering of Shares

Evoke Pharma Completes Underwriters Exercise Of Full Over-Allotment Option Of IPO For USD29 Million

Evoke Pharma Inc-Key Competitors

Evoke Pharma Inc-Key Employees

Evoke Pharma Inc-Locations And Subsidiaries

Head Office

Recent Developments

Financial Announcements

Mar 07, 2018: Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights

Nov 14, 2017: Evoke Pharma Reports Third Quarter 2017 Results and Highlights

Aug 14, 2017: Evoke Pharma Reports Second Quarter 2017 Results and Highlights

May 15, 2017: Evoke Pharma Reports First Quarter 2017 Results

May 15, 2017: Evoke Pharma Q1 net loss increases

Mar 15, 2017: Evoke Pharma Reports Fourth Quarter and Full Year 2016 Results

Product News

10/27/2017: Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure Pharmacokinetic Study for Gimoti

10/23/2017: Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti

10/04/2017: Evoke Pharma to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference

09/05/2017: Evoke Pharma to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

05/15/2017: Evoke Pharma Provides Update on Gimoti

02/15/2018: Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti

Product Approvals

Sep 12, 2017: Evoke Pharma Completes Dosing for Gimoti Comparative Exposure Pharmacokinetic Study

Aug 14, 2017: Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti

May 31, 2017: Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti

Apr 04, 2017: Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma's Proposed Comparative Exposure PK Trial for Gimoti NDA

Feb 15, 2017: FDA Exempts Evoke from Requirement for Human Factor Validation Study

Clinical Trials

May 10, 2017: Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week 2017

Mar 21, 2017: Evoke Pharmas Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017

Jan 09, 2017: Evoke Pharma to Attend 2017 JPMorgan Healthcare Conference

Jan 04, 2017: Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Evoke Pharma Inc, Medical Devices Deals, 2012 to YTD 2018

List of Tables

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Evoke Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018

Evoke Pharma Inc, Medical Devices Deals, 2012 to YTD 2018

Evoke Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Evoke Pharma Enters into Agreement with Thermo Fisher Scientific

Evoke Pharma Enters into Partnership with Spaulding Clinical Research

Evoke Pharma Plans to Raise up to USD16 Million in Public Offering of Shares

Evoke Pharma Raises USD8 Million in Public Offering of Shares

Evoke Pharma Raises USD4.5 Million in Registered Direct Offering

Evoke Pharma to Raise USD10 Million in Registered Direct Offering

Evoke Pharma Raises USD5 Million in Public Offering of Shares

Evoke Pharma to Raise Funds through Public Offering of Shares

Evoke Pharma Completes Underwriters Exercise Of Full Over-Allotment Option Of IPO For USD29 Million

Evoke Pharma Inc, Key Competitors

Evoke Pharma Inc, Key Employees

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com